101 related articles for article (PubMed ID: 11150587)
1. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity.
Josić D; Hoffer L; Buchacher A; Schwinn H; Frenzel W; Biesert L; Klöcking HP; Hellstern P; Rokicka-Milewska R; Klukowska A
Thromb Res; 2000 Dec; 100(5):433-41. PubMed ID: 11150587
[TBL] [Abstract][Full Text] [Related]
2. A fully recombinant partial prothrombin complex effectively bypasses fVIII in vitro and in vivo.
Himmelspach M; Richter G; Muhr E; Varadi K; Turecek PL; Dorner F; Schwarz HP; Schlokat U
Thromb Haemost; 2002 Dec; 88(6):1003-11. PubMed ID: 12529752
[TBL] [Abstract][Full Text] [Related]
3. Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
Bardin JM; Sultan Y
Transfusion; 1990 Jun; 30(5):441-3. PubMed ID: 2360238
[TBL] [Abstract][Full Text] [Related]
4. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency.
Hellstern P
Thromb Res; 1999 Aug; 95(4 Suppl 1):S7-12. PubMed ID: 10499903
[TBL] [Abstract][Full Text] [Related]
5. Chromatographic purification and properties of a therapeutic human protein C concentrate.
Radosevich M; Zhou FL; Huart JJ; Burnouf T
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jun; 790(1-2):199-207. PubMed ID: 12767332
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
7. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
[TBL] [Abstract][Full Text] [Related]
9. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.
Holland L; Warkentin TE; Refaai M; Crowther MA; Johnston MA; Sarode R
Transfusion; 2009 Jun; 49(6):1171-7. PubMed ID: 19210325
[TBL] [Abstract][Full Text] [Related]
10. Assessment of thrombogenicity of activated and non-activated prothrombin concentrates in a rat model.
Silberman S; Fareed J; Walenga J
Br J Exp Pathol; 1986 Aug; 67(4):597-604. PubMed ID: 3091059
[TBL] [Abstract][Full Text] [Related]
11. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
[TBL] [Abstract][Full Text] [Related]
12. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
13. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
14. Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.
Pabinger-Fasching I
Thromb Res; 2008; 122 Suppl 2():S19-22. PubMed ID: 18549908
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate.
Morfini M; Longo G; Berntorp E; Cinotti S; Filimberti E; Messori A; Nilsson IM; Rossi Ferrini P
Thromb Res; 1993 Aug; 71(3):175-84. PubMed ID: 8211885
[TBL] [Abstract][Full Text] [Related]
17. A method for systematic purification from bovine plasma of six vitamin K-dependent coagulation factors: prothrombin, factor X, factor IX, protein S, protein C, and protein Z.
Hashimoto N; Morita T; Iwanaga S
J Biochem; 1985 May; 97(5):1347-55. PubMed ID: 3161875
[TBL] [Abstract][Full Text] [Related]
18. Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX).
Girolami A; Ferrari S; Cosi E; Santarossa C; Randi ML
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):42S-47S. PubMed ID: 30428703
[TBL] [Abstract][Full Text] [Related]
19. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
20. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
